Bioventus (BVS) vs SI-BONE (SIBN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bioventus (BVS) has outperformed SI-BONE (SIBN) over the past year, gaining 92.0% versus a gain of 24.6%. Over five years, BVS leads with a -6.4% price change compared with -16.4% for SIBN. Bioventus is the larger company by market cap ($872.3 million vs $856.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | SIBN |
|---|---|---|
| Share price | $12.77 | $19.10 |
| Market cap | $872.26M | $856.03M |
| 1-day change | -2.52% | -2.30% |
| YTD return | +71.64% | -3.14% |
| 1-year return | +92.03% | +24.59% |
| 5-year return | -6.38% | -16.41% |
| P/E ratio (TTM) | 16.80 | — |
| Forward P/E | 13.88 | — |
| EPS (TTM) | $0.76 | $-0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.89 | $21.89 |
| 52-week low | $6.37 | $11.48 |
| Distance from 52-week high | -19.65% | -12.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +37.82% | +32.04% |
| Average volume | 623.67K | 541.04K |
| Shares outstanding | 68.31M | 44.82M |
| Employees | 950 | 376 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed SIBN by 67.4 percentage points over the past year.
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Healthcare · Medical Devices · 950 employees
About SI-BONE
SIBN stock →SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products.
Healthcare · Medical Devices · 376 employees
BVS vs SIBN FAQ
Which is bigger, Bioventus or SI-BONE?
Bioventus (BVS) is larger, with a market capitalization of $872.26M compared with $856.03M for SI-BONE (SIBN).
Which stock has performed better over the past year, BVS or SIBN?
BVS returned +92.03% over the past 12 months, compared with +24.59% for SIBN (price return, excluding dividends). Past performance does not predict future results.
Are Bioventus and SI-BONE in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.